The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
PARP inhibitors (PARPi) have shown promising clinical results and have revolutionized the landscape of ovarian cancer management in the last few years. While the core mechanism of action of these drugs has been largely analyzed, the interaction between PARP inhibitors and the microenvironment has be...
Main Authors: | Margherita Turinetto, Giulia Scotto, Valentina Tuninetti, Gaia Giannone, Giorgio Valabrega |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.689829/full |
Similar Items
-
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
by: Gaia Giannone, et al.
Published: (2020-06-01) -
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
by: Gaia Giannone, et al.
Published: (2019-05-01) -
The Multifactorial Role of PARP-1 in Tumor Microenvironment
by: Juan Manuel Martí, et al.
Published: (2020-03-01) -
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
by: Fulvio Borella, et al.
Published: (2020-03-01) -
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
by: Alexandra S. Zimmer, et al.
Published: (2019-07-01)